Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by China’s National Medical Products Administration (NMPA) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. This… read more.
Jascayd (nerandomilast) tablets has been approved by the FDA as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. Jascayd is the first and only… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
